Literature DB >> 10884617

The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis.

R A Slayden1, C E Barry.   

Abstract

Although the primary targets of activated isoniazid (INH) are proteins involved in the biosynthesis of cell wall mycolic acids, clinical resistance is dominated by specific point mutations in katG. Mutations associated with target mutations contribute to, but still cannot completely explain, resistance to INH. Despite the wealth of genetic information currently available, the molecular mechanism of cell death induced by INH remains elusive.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884617     DOI: 10.1016/s1286-4579(00)00359-2

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  61 in total

1.  High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001.

Authors:  Igor Mokrousov; Olga Narvskaya; Tatiana Otten; Elena Limeschenko; Lidia Steklova; Boris Vyshnevskiy
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.

Authors:  Paolo Miotto; Federica Piana; Valeria Penati; Filippo Canducci; Giovanni Battista Migliori; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

3.  Multiplex real-time PCR melting curve assay to detect drug-resistant mutations of Mycobacterium tuberculosis.

Authors:  Tao Luo; Lili Jiang; Weiming Sun; G Fu; Jian Mei; Qian Gao
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

Review 4.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

5.  Improved rapid molecular diagnosis of multidrug-resistant tuberculosis using a new reverse hybridization assay, REBA MTB-MDR.

Authors:  Hyeeun Bang; Sangjung Park; Joohwan Hwang; Hyunwoo Jin; Eunjin Cho; Dae Yoon Kim; Taeksun Song; Isdore Chola Shamputa; Laura E Via; Clifton E Barry; Sang-Nae Cho; Hyeyoung Lee
Journal:  J Med Microbiol       Date:  2011-05-19       Impact factor: 2.472

6.  Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China.

Authors:  Tao Luo; Ming Zhao; Xia Li; Peng Xu; Xiaohong Gui; Sam Pickerill; Kathryn DeRiemer; Jian Mei; Qian Gao
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

7.  Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.

Authors:  Yingda L Xie; Soumitesh Chakravorty; Derek T Armstrong; Sandra L Hall; Laura E Via; Taeksun Song; Xing Yuan; Xiaoying Mo; Hong Zhu; Peng Xu; Qian Gao; Myungsun Lee; Jongseok Lee; Laura E Smith; Ray Y Chen; Joon Sung Joh; YoungSoo Cho; Xin Liu; Xianglin Ruan; Lili Liang; Nila Dharan; Sang-Nae Cho; Clifton E Barry; Jerrold J Ellner; Susan E Dorman; David Alland
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

8.  Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities.

Authors:  Christine E Cade; Adrienne C Dlouhy; Katalin F Medzihradszky; Saida Patricia Salas-Castillo; Reza A Ghiladi
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

9.  Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo.

Authors:  Graham S Timmins; Sharon Master; Frank Rusnak; Vojo Deretic
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

10.  Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance.

Authors:  Indra L Bergval; Anja R J Schuitema; Paul R Klatser; Richard M Anthony
Journal:  J Antimicrob Chemother       Date:  2009-07-04       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.